Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-07820-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Angelique Loor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antibodies, Monoclonal, Humanized, Camptothecin, Alpha Particles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Purpose
Ovarian cancer (OC) is frequently diagnosed at late stages after metastasis and chemorefractive leading to poor survival outcomes. There is a critical need for earlier detection and novel antigen-targeted therapies to improve patient survival at all stages. TROP-2 is a transmembrane glycoprotein overexpressed in many cancers and presents a promising target for OC. Recently, antibody-drug conjugates such as sacituzumab govitecan (SG) and datopotamab deruxtecan have been approved for various TROP-2-positive malignancies such as metastatic breast, lung, or urothelial cancer. However, diagnosis is based on prior therapy failure and TROP-2 therapy focused on antibody-drug conjugates.
Methods
Minimal radiotheranostic versions of SG were developed for immunoPET imaging with [ 89 Zr]Zr-DFO-SG in flank and intraperitoneal OVCAR3 implants. IHC was also done to identify other OC models that express Trop2. Radiotherapy variants of SG [ 177 Lu]Lu-DTPA-SG, [ 225 Ac]Ac-mcp-Direct-SG, or [ 225 Ac]Ac-mcp-Click-SG were also made and tested for efficacy alongside the standard of care SG. Results [ 177 Lu]Lu-DTPA-SG delayed tumor recurrence for up 6–8 weeks post-treatment and retreatment prolonged overall survival to 21 weeks matching standard of care SG dosing. Between two linkers, [ 225 Ac]Ac-mcp-Direct-SG was found to yield a superior minimal conjugation of SG than [ 225 Ac]Ac-mcp-Click-SG, with better tumor targeting by biodistribution and prolonged reduction in OC over 30 weeks.
Conclusion
Ultimately, utility of SG was improved through minimal modification of the ADC and applied a “treat what you see” approach to TROP-2-positive OC. By using a new tetrafluorophenyl linkage of macropa, [ 225 Ac]Ac-mcp-Direct-SG greatly reduced tumor burden in OC with most mice surviving and tolerating the therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. edwin.pratt@stonybrookmedicine.edu.
- Stony Brook University Cancer Center, Stony Brook, NY, USA. edwin.pratt@stonybrookmedicine.edu.
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lewisj2@mskcc.org.
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA. lewisj2@mskcc.org.
Förderung
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Loor, A., Mack, K. N., Bauer, D., Ingham, A., Pratt, E. C., & Lewis, J. S. (2026). Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07820-7
Vancouver
Loor A, Mack KN, Bauer D, Ingham A, Pratt EC, Lewis JS. Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07820-7
BibTeX
@article{Loor2026,
author = {Loor, Angelique and Mack, Kyeara N and Bauer, David and Ingham, Aidan and Pratt, Edwin C and Lewis, Jason S},
title = {Minimal chemical modification enables alpha/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-07820-7}
}
EUVIMED